Eliciting distributions to populate decision analytic models.
暂无分享,去创建一个
Karl Claxton | Mark Sculpher | Laura Bojke | Keith Abrams | Stephen Palmer | S. Palmer | M. Sculpher | K. Claxton | K. Abrams | L. Bojke | Y. Bravo-Vergel | Yolanda Bravo-Vergel
[1] Andrew H. Briggs,et al. Handling Uncertainty in Cost-Effectiveness Models , 2000, PharmacoEconomics.
[2] Karl Claxton,et al. Characterizing structural uncertainty in decision analytic models: a review and application of methods. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[3] Simon G Thompson,et al. Accounting for uncertainty in health economic decision models by using model averaging , 2009, Journal of the Royal Statistical Society. Series A,.
[4] M. Brodmann,et al. Successful bosentan treatment of critical ischaemia induced by vasculitis in an SCLE patient. , 2008, Rheumatology.
[5] I. Bruce,et al. The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis. , 2007, Rheumatology.
[6] Andrew M. Jones. The Elgar Companion to Health Economics , 2007 .
[7] Sarah Wordsworth,et al. Eliciting expert opinion for economic models: an applied example. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[8] I. Bruce,et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review. , 2006, Clinical and experimental rheumatology.
[9] A. O'Hagan,et al. The Elicitation of Probabilities , 2006 .
[10] Jeremy E. Oakley,et al. Uncertain Judgements: Eliciting Experts' Probabilities , 2006 .
[11] Grazyna Adamiak,et al. Methods for the economic evaluation of health care programmes, 3rd ed , 2006 .
[12] M Sculpher,et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. , 2006, Health technology assessment.
[13] M. Sculpher,et al. Decision-making with Uncertainty: The Value of Information , 2006 .
[14] A E Ades,et al. The Interpretation of Random-Effects Meta-Analysis in Decision Models , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.
[15] A. O'Hagan,et al. Statistical Methods for Eliciting Probability Distributions , 2005 .
[16] M. Sculpher,et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. , 2005, Health economics.
[17] David Jenkinson,et al. The Elicitation of Probabilities-A Review of the Statistical Literature , 2005 .
[18] M Sculpher,et al. A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme. , 2004, Health technology assessment.
[19] M C Weinstein,et al. Bayesian value-of-information analysis. An application to a policy model of Alzheimer's disease. , 2001, International journal of technology assessment in health care.
[20] Alex J. Sutton,et al. Methods for Meta-Analysis in Medical Research , 2000 .
[21] K Claxton,et al. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. , 1999, Journal of health economics.
[22] Robert L. Winkler,et al. Combining Probability Distributions From Experts in Risk Analysis , 1999 .
[23] Beichelt Frank,et al. IEEE Trans. Reliab. , 1992 .
[24] Roger M. Cooke,et al. Expert judgment in maintenance optimization , 1992 .
[25] R. Cooke. Experts in Uncertainty: Opinion and Subjective Probability in Science , 1991 .
[26] S. Wilson. Methods for the economic evaluation of health care programmes , 1987 .
[27] Christian Genest,et al. Combining Probability Distributions: A Critique and an Annotated Bibliography , 1986 .